Aurinia Pharmaceuticals Inc. (AUPH) Earns “Outperform” Rating from Leerink Swann
Leerink Swann restated their outperform rating on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a report released on Monday morning. They currently have a $7.00 price objective on the stock.
Several other research firms have also issued reports on AUPH. FBR & Co reissued an outperform rating and issued a $9.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday, August 15th. Canaccord Genuity set a $10.00 price target on shares of Aurinia Pharmaceuticals and gave the stock a buy rating in a research report on Friday, August 5th. Finally, HC Wainwright assumed coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, June 30th. They set a buy rating and a $7.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of Buy and an average target price of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.05 on Monday. The firm’s market capitalization is $142.91 million. The stock’s 50 day moving average price is $2.30 and its 200 day moving average price is $2.75. Aurinia Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $4.49.
A hedge fund recently raised its position in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp increased its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned approximately 0.29% of Aurinia Pharmaceuticals worth $283,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 20.04% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.